Ronan Kelly, MD, MBA, is the director of the Charles A. Sammons Cancer Center at Baylor University Medical Center in Dallas, Texas, and the chief of oncology for the Baylor Scott & White Health System (north Texas). Dr. Kelly is also a clinical professor at Texas A&M University and remains an adjunct associate professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.
He previously served as the director of the Gastroesophageal Cancer Therapeutics Program at Johns Hopkins University and as the director of Global Oncology for Johns Hopkins International. In the latter role, Dr. Kelly was responsible for improving the quality of cancer care in all Johns Hopkins-affiliated hospitals across four continents. He performs translational and clinical research encompassing the discovery and development of newly targeted and immunotherapeutic approaches for the prevention and treatment of gastroesophageal cancer and lung cancer.
Dr. Kelly is the national and international principal investigator on numerous ongoing phase II and phase III studies that investigate single agent and combination checkpoint inhibitors in locally advanced and metastatic gastroesophageal cancer. He is also the author or co-author of more than 150 publications, including peer-reviewed journal articles, abstracts, and book chapters.